Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Abstract

Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 10 10 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs 71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; p interaction =0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. Funding UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca.

Cited by papers we hold 92

• Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis · 2023
  No notice
• Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases · 2023
  No notice
• Confidence interval estimation for vaccine efficacy against COVID-19 · 2022
  Not checked
• Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination · 2022
  No notice
• Impact of age, sex and medical history on adverse reactions to the first and second dose of BNT162b2 mRNA COVID-19 vaccine in Japan: a cross-sectional study · 2022
  Not checked
• Reactogenicidad de la vacuna Sputnik V en los estudiantes de medicina. Universidad de Carabobo · 2022
  Not checked
• A novel vaccine based on SARS-CoV-2 CD4+ and CD8+ T cell conserved epitopes from variants Alpha to Omicron · 2022
  Not checked
• Recent Update of COVID-19 Vaccines · 2022
  Not checked
• To what extent AstraZeneca ChAdOx1 nCoV-19 vaccine is safe and effective? Rapid systematic review · 2022
  Not checked
• Bilateral acute macular neuroretinopathy in a young woman after the first dose of Oxford–AstraZeneca COVID-19 vaccine · 2022
  Not checked
• Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors · 2022
  No notice
• Longevity of vaccine protection: Immunological mechanism, assessment methods, and improving strategy · 2022
  Not checked
• Therapeutic peptides: current applications and future directions · 2022
  No notice
• Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines · 2022
  No notice
• Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines · 2022
  No notice
• SARS-COV-2 Variants: Differences and Potential of Immune Evasion · 2022
  No notice
• SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway · 2022
  Corrected
• The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: A systematic review and meta-analysis · 2022
  No notice
• Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study · 2022
  No notice
• Systematic review and meta-analysis of the effectiveness and perinatal outcomes of COVID-19 vaccination in pregnancy · 2022
  No notice

and 72 more

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.